Chronic human illness reflects dysfunction in multiple biological pathways. Given the complexity, discovery strategies based on “one-target, one-disease” are proving increasingly unsuccessful. Acquist programs focus on agents that modulate multiple targets simultaneously, as “bifunctional” or “bispecific” drugs. Addressing cellular functions as a system, rather than a single-target, may lead to novel classes of effective multi-targeted drugs with fewer side-effects.